Top Ten most popular articles on Pharmafile.com this week
pharmafile | March 16, 2018 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Andrew Witty, AstraZeneca, BMS, Biocon, Martin Shkreli, Novartis, Right to try, US, pharma, top ten
Another week goes by, and we may have finally reached Spring here in the UK. Friday means its time for another rundown of the top ten most popular articles on Pharmafile.com over the past seven days, and its been an eventful period to say the least.
The infamous “most hated man in America” Martin Shkreli’s crimes finally caught up with him, as he was sentned to seven years jail time on counts of fraud, and the divisive “right-to-try” bill in the US was defeated by a slim margin in the House of Representatives. However, the most popular story this week was the news that Biocon, India’s largest pharma firm, has received warnings from the FDA over cGMP failures at its Malaysia facility – issues which it has assured us and the US regulator it is on the way to promptly rectifying.
Check out the week’s ten most popular articles on Pharmafile.com here:
10. Martin Shkreli sentenced to seven years in jail for securities fraud
Three years after he became “the most hated man in America” overnight for jacking up the price of life-saving HIV-related toxoplasmosis drug Daraprim by 5,000%, Martin Shkreli has now been sentenced to seven years in jail for charges of securities fraud.
9. US “right to try” experimental drug bill defeated in House vote
The divisive and much-talked-about “right to try” legislation designed to provide access for terminally ill Americans to experimental and unproven drugs has been defeated on the House floor, with 259 for and 140 against.
8. World’s first synthetic, non-biologic vaccine developed
Researchers from Cardiff University may have discovered a way to bypass the challenge of keeping vaccines in a cool environment, by creating the world’s first synthetic, non-biologic vaccine for influenza.
7. AstraZeneca’s Brilinta proves safety in heart attack patients at Phase 3
AstraZeneca has revealed new Phase 3 data on Brilinta showing that the drug met its primary endpoint in heart attack patients treated with pharmacological thrombolysis.
6. BMS restructure will transfer 90 jobs from NY state to Massachusetts and New Jersey
Bristol-Myers Squibb has announced plans to relocate around 90 roles from the state of New York to facilities in Massachusetts and New Jersey as part of a restructuring effort.
5. Andrew Witty takes on a new CEO position
Andrew Witty, who made his name working his way up the ranks at GSK to become its CEO, has revealed his next move after retiring from the position, by becoming CEO at Optum, part of the UnitedHealth Group.
4. AbbVie secures further strong results for potential blockbuster
AbbVie’s elagolix has been slated as a blockbuster-in-the-making by analysts predicting big things for the potential treatment for uterine fibroids and endometriosis, the release of strong data supports this expectation.
3. GSK loses £37m appeal over pay-to-delay tactics to block Seroxat competition
GlaxoSmithKline has suffered a sizeable blow after losing an appeal disputing that it had engaged in anti-competitive pay-to-delay tactics to block generic versions of its blockbuster antidepressant Seroxat (paroxetine) from reaching the market.
2. Novartis reshuffle begins under new CEO
It’s a common strategy that newly appointed CEOs will try to change the direction of the company via rejigging leadership positions, and it looks like Novartis’ new CEO is following this trend with a few eye-opening promotions.
1. FDA inspection reveals cGMP issues at Biocon’s major Malaysia facility
Biocon’s insulin production facility in Johar, Malaysia has been slapped with six observations from the US FDA following an inspection which took place between the 6 and 15 February.
Related Content
Novartis receives SMC approval for early breast cancer treatment
Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …
Sharp invests $100m in US and EU manufacturing and packaging facilities
Sharp Services, a pharmaceutical packaging and sterile manufacturing specialist, has announced investments totalling $100m across …
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
